



FOR IMMEDIATE RELEASE:

January 25, 2021

Paul Zhang Hosts China Innovative Pharma Panel at the 2021 China Focus Conference

On January 10, 2021, Paul Zhang, Partner at Bluestar BioAdvisors LLC hosted a panel discussion titled “**The Dawn of Innovative Pharmaceutical Market in China**” during the annual China Focus conference, which took place simultaneously with the 39th virtual JP Morgan Healthcare Conference. Paul was joined by the following senior leaders of four innovative Chinese biotechnology companies:

- Ying Huang – CEO, Legend Biotech
- Atul Deshpande – Chief Strategy Officer & Head of US Operations, Harbour BioMed
- Weimin Tang – Global Business Head and Executive VP, I-Mab Biopharma
- Wenjun Sun – VP and Head of BD, JW Therapeutics

During an hour-long discussion, the panelists shared their perspectives on the rapidly evolving pharmaceutical market in China, as well as the opportunities and challenges facing innovative biotechnology companies. The panelists engaged in discussions around key topics:

- How to build a portfolio of products in an environment where pricing is under pressure? What is the ideal business model?
 - Is first-in-class a must for sustainable growth?
 - What is the best way to generate value for investors in the long run?
 - Is it more attractive to be a China-focused biotech or a global biotech with a China market angle?
- Oncology market has been hot in China. What will come next?
- What is the permanent mark that COVID-19 pandemic will leave on the biotech industry in 2021 and beyond?

The panelists were energized by the rapid development of healthcare reform policies and biopharmaceutical ecosystem in China, and debated a number of strategic imperatives to meet currently urgent pricing challenges. Going global is a strong sentiment for this new generation of Chinese biotechnology companies.

To access the panel video recording, register at <https://events.mybiogate.com/>

FOR IMMEDIATE RELEASE:

January 25, 2021

About Bluestar BioAdvisors

Bluestar BioAdvisors, LLC is an expertise-based boutique consultancy dedicated to the life sciences industry. Its leadership team consists of senior members with consulting and industry expertise. We focus on addressing the commercial opportunities and challenges of pipeline stage assets, leading to actionable strategies on the global scale.

Source: Bluestar BioAdvisors LLC.

Contact:

Paul Zhang

Partner

PZhang@bluestarbio.com

o: (212) 257-5815 m: (908) 392-6088